Copyright ©The Histochemical Society, Inc.

Ultrastructural Localization of Platelet Endothelial Cell Adhesion Molecule (PECAM-1, CD31) in Vascular Endothelium

Dian Feng, Janice A. Nagy, Kathryn Pyne, Harold F. Dvorak and Ann M. Dvorak

Departments of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts

Correspondence to: Dr. Ann M. Dvorak, Dept of Pathology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215. Fax: 617-667-2943


    Summary
 Top
 Summary
 Introduction
 Materials and Methods
 Results
 Discussion
 Literature Cited
 
The distribution of platelet endothelial cell adhesion molecule (PECAM-1, CD31) in vascular endothelium has been disputed. Originally reported to be highly concentrated at interendothelial cell contacts, recent studies have claimed that CD31 is distributed evenly over the entire endothelial cell surface. We re-investigated this question with two different murine anti-CD31 antibodies (MEC 13.3 and M-20), using a pre-embedding immunonanogold electron microscopic procedure that allowed precise label quantitation. MEC 13.3 reacted strongly with the luminal and abluminal plasma membranes of the endothelial cells lining microvessels in normal tissues and in angiogenic vessels induced by a tumor and vascular endothelial growth factor (VEGF-A164). Lateral plasma membranes were significantly less labeled. Conversely, M-20 strongly labeled the cytoplasmic face of the lateral plasma membranes of endothelial cells, although sparing specialized junctions, and only weakly labeled the luminal and abluminal plasma membranes. Both antibodies stained a significant minority of vesicles and vacuoles comprising the vesiculovacuolar organelle (VVO). Neither antibody was reactive in CD31-null mice. We conclude that CD31 is distributed over the entire endothelial cell surface, exclusive of specialized junctions, and in VVOs, but is not equally accessible to different antibodies in all locations.

(J Histochem Cytochem 52:87–101, 2004)

Key Words: endothelial cells • CD31 • PECAM-1 • VEGF-A • nanogold • immunocytochemistry • VVOs • electron microscopy


    Introduction
 Top
 Summary
 Introduction
 Materials and Methods
 Results
 Discussion
 Literature Cited
 
Platelet endothelial cell adhesion molecule (PECAM-1, CD31) is a ~130 kD glycoprotein that is constitutively expressed by endothelial cells and by platelets, neutrophils, monocytes, and some T-lymphocytes (Muller et al. 1989Go,1993Go; Vaporciyan et al. 1993Go; Carlos and Harlan 1994Go; Newman 1994Go,1997Go; Muller 1995aGo; Muller and Randolph 1999Go; Liao et al. 1999Go; Newton–Nash and Newman 1999Go; Henshall et al. 2001Go; Ilan et al. 2001Go; Newman et al. 2001Go; Jackson 2003Go; Cicmil et al. 2002Go; Newman and Newman 2003Go). It is an integral transmembrane protein that belongs to the immunoglobulin superfamily and that mediates both homotypic and heterotypic cell adhesion. These functions have implicated CD31 in a variety of important biological processes including inflammation, angiogenesis and wound healing (Schimmenti et al. 1992Go; Muller et al. 1993Go; Muller 1995aGo; Murohara et al. 1996Go; DeLisser et al. 1997Go; Newman 1997Go; Zhou et al. 1999Go; Cao et al. 2002Go; Jackson 2003Go; Newman and Newman 2003Go). In particular, CD31 has an important role in neutrophil and monocyte emigration across vascular endothelium, processes that can be inhibited, both in vitro and in vivo, with anti-CD31 antibodies (Bogen et al. 1992Go; Muller et al. 1993Go; Liao et al. 1995Go; Rival et al. 1996Go; Zocchi et al. 1996Go; Christofidou–Solomidou et al. 1997Go; Newman 1997Go).

Immunohistochemical (IHC) studies demonstrated that CD31 is distributed diffusely on the surfaces of inflammatory cells and platelets (Ohto et al. 1985Go; Metzelaar et al. 1991Go; Bogen et al. 1992Go; Newman et al. 1992Go). However, initial light microscopic studies of cultured endothelial cells in vitro and of the vasculature in vivo reported that CD31 was concentrated at the lateral borders of endothelial cells, i.e., at sites of interendothelial cell contact (Muller et al. 1989Go,1993Go; Albelda et al. 1990Go; Metzelaar et al. 1991Go; Vaporciyan et al. 1993Go; Ayalon et al. 1994Go; Carlos and Harlan 1994Go; Newman 1994Go,1997Go; Zocchi et al. 1996Go). These findings were believed to reflect homotypic binding in which CD31 joined together adjacent endothelial cells. They were also consistent with studies demonstrating that anti-CD31 antibodies inhibited leukocyte extravasation, a process that was believed to involve the passage of inflammatory cells through interendothelial cell junctions (Muller et al. 1989Go,1993Go; Muller 1995aGo,bGo; Muller and Randolph 1999Go).

Not all studies have agreed that CD31 is concentrated on the lateral membranes of endothelial cells. Some reports have found CD31 to be distributed diffusely on the surfaces of vascular and lymphatic endothelium (Ioffreda et al. 1993Go; Grafe et al. 1994Go; Erhard et al. 1996Go; Scholz and Schaper 1997Go; Lossinsky and Wisniewski 1998Go; Sauter et al. 1998Go; Marszalek et al. 2000Go; Ebata et al. 2001Go). Moreover, it has been claimed that CD31 is normally distributed widely over the surface of vascular endothelium in vivo but that, in response to TNF-{alpha} or other types of activation, CD31 is redistributed to the lateral plasma membranes (Ioffreda et al. 1993Go).

Our interest in CD31 was prompted by our studies of neutrophil emigration at sites of inflammation in guinea pig skin (Feng et al. 1998Go). Making use of serial electron microscopic sections and computer-assisted reconstructions, we demonstrated that, in response to an inflammatory stimulus, f-Met-Leu-Phe (FMLP), neutrophils extravasated by a transcellular, parajunctional pathway through greatly thinned endothelial cells, not by passing through interendothelial clefts. Interendothelial clefts were not widened and endothelial cell junctions remained tightly closed. Our findings therefore appeared to predict that anti-CD31 antibodies acted to inhibit neutrophil transmigration across endothelium in some fashion other than that of interfering with the opening of interendothelial junctions.

To further investigate this question, we investigated the ultrastructural distribution of CD31 in the microvasculature of a number of different tissues and organs in normal mice, in mouse tumor vessels, and in the new angiogenic vessels induced in flank skin by an adenovirus engineered to express vascular permeability factor/vascular endothelial growth factor (VPF/VEGF, VEGF-A164) (Pettersson et al. 2000Go). To our surprise, we found that two antibodies directed at different portions of the CD31 molecule gave distinctly different distributions in vascular endothelium, suggesting that these differences may be important for understanding the physiological and pathological functions of CD31.


    Materials and Methods
 Top
 Summary
 Introduction
 Materials and Methods
 Results
 Discussion
 Literature Cited
 
Animals, Tumors, and Adenoviral Vector
We studied blood vessels in 4–6-week-old female mice, as follows: three normal A/Jax mice, two CD31-null mice (B6;129S-Pecamtm1Lex), two B6;129S-F2/J mice that served as controls for the CD31-nulls (all obtained from the Jackson Laboratory; Bar Harbor, ME), and two athymic Nu/Nu mice (National Cancer Institute; Bethesda, MD). For studies of tumor blood vessels, 1 x 106 TA3/St mammary carcinoma cells were injected into the SC space of three syngeneic A/Jax mice and tumors were harvested 9 days later (Feng et al. 2000bGo). For additional studies of angiogenic blood vessels, an adenoviral vector engineered to express VEGF-A164 (Ad-VEGF-A164) was prepared as previously described (Pettersson et al. 2000Go). Plaque-forming units (108) were injected into the flank skin of two 4–6-week-old-female athymic Nu/Nu mice in a volume of 5 µl through a 30-g needle and tissue was harvested for study of new blood vessels 4 days later.

Antibodies to CD31
A rat monoclonal antibody (MAb) to CD31 (clone MEC 13.3, IgG2ak) was obtained from Pharmingen (San Diego, CA). MEC 13.3 was prepared by immunizing with a polyoma middle T transformed endothelial cell line (Vecchi et al. 1994Go). It has been widely used to stain CD31 on vascular endothelium (Vecchi et al. 1994Go; Christofidou–Solomidou et al. 1997Go; Zhou et al. 1999Go), effectively blocks neutrophil accumulation in the inflamed mouse peritoneum and in TNF-{alpha}-stimulated skin grafts (Christofidou–Solomidou et al. 1997Go), and blocks FGF-induced angiogenesis (DeLisser et al. 1997Go). An affinity-purified goat polyclonal IgG antibody raised against a 20-amino-acid peptide mapping at the carboxy terminus of mouse CD31 (M-20) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). A goat polyclonal IgG directed against an epitope at the carboxy terminus of human VE-cadherin (C-19) was also obtained from Santa Cruz.

Tissue Fixation and Processing for Immunocytochemistry
Mice were sacrificed by CO2 narcosis and tissues were immediately fixed in 4% paraformaldehyde in 0.02 M PBS, pH 7.4, for 4 hr at room temperature (RT), washed in 0.02 M PBS, pH 7.4, and immersed overnight in 4C 30% sucrose in 0.02 M PBS, pH 7.4 (Feng et al. 2000aGo). Issues were then embedded in OCT compound (Miles; Elkhart, IN) and stored in liquid nitrogen.

Immunonanogold Silver Staining Protocol for Electron Microscopy
Tissue was processed for immunonanogold staining and electron microscopy as previously described (Feng et al. 2000aGo). In brief, 10-µm cryostat tissue sections were cut, collected on pre-cleaned glass slides, and air-dried for 20 min. All following steps were performed at RT: (a) wash in 0.02 M PBS, pH 7.4, 5 min; (b) immerse in 50 mM glycine in 0.02 M PBS, pH 7.4, 10 min; (c) wash in 0.02 M PBS, pH 7.4, 5 min; (d) immerse in 5% normal goat serum (NGS) (Vector Laboratories; Burlingame, CA), 20 min; (e) incubate in the primary antibody (MEC 13.3, M-20, or C-19) at dilutions of 1:25, 1:50, or 1:100 in 0.02 M PBS, 60 min; (f) three washes in 0.02 M PBS, pH 7.4, 5 min each; (g) incubate in the secondary antibody (affinity-purified goat anti-rat or rabbit anti-goat Fab1 conjugated to 1.4-nm nanogold) (Nanoprobes; Stony Brook, NY), 1:50 or 1:100 in 0.02 M PBS, pH 7.4, 60 min; (h) three washes in 0.02 M PBS, pH 7.4, 5 min each; (i) postfix in 1% glutaraldehyde in 0.02 M PBS, pH 7.4, 2 min (j) three washes in distilled water, 5 min each; (k) develop with HQ silver enhancement solution (Nanoprobes) for 6 min in the darkroom; (l) two washes in distilled water, 2 min each; (m) fix in 5% sodium thiosulfate, 1 min; (n) three washes in distilled water, 5 min each; (o) postfix in 1% osmium tetroxide in sym-collidine buffer, pH 7.4, 10 min; (p) one wash in 0.05 M sodium maleate buffer, pH 5.2, 5 min; (q) stain with 2% uranyl acetate in 0.05 M sodium maleate buffer, pH 6.0, 5 min; (r) one wash in distilled water, 5 min; (s) dehydrate in graded ethanols and infiltrate with a propylene oxide-eponate (Ted Pella; Redding, CA) sequence; (t) embed by inverting eponate-filled plastic capsules over the slide-attached tissue sections; (u) polymerize at 60C for 16 hr; (v) separate eponate blocks from glass slides by brief immersion in liquid nitrogen; (w) cut thin sections with a diamond knife with an ultratome (Reichert; Vienna, Austria), and collect sections on uncoated 200-mesh copper grids (Ted Pella); (x) view grids with a transmission electron microscope (CM-10; Philips, Einhoven, The Netherlands) without additional staining.

Controls for Immunonanogold Staining
Four controls were performed to ensure the specificity of staining: (a) replacement of the primary antibody by an irrelevant goat anti-rat or rabbit anti-goat antibody; (b) omission of specific primary antibody; (c) omission of the secondary antibody; and (d) omission of the HQ silver enhancement solution.

Quantitation of Immunonanogold Label
Silver-enhanced immunonanogold particles were counted on randomly selected electron micrographs of capillary and venule endothelial cells of normal mouse skin and heart, nude mouse lung, and hyperpermeable vessels induced by tumors or Ad-VEGF-A164. The subcellular localization of label on luminal, abluminal, and lateral plasma membranes was expressed as particles/linear micrometer of membrane or as percent of labeling of individual vesicles and vacuoles comprising VVOs. Statistical analysis was performed using the Mann–Whitney U-test.


    Results
 Top
 Summary
 Introduction
 Materials and Methods
 Results
 Discussion
 Literature Cited
 
Ultrastructural Distribution of CD31 on Normal Microvessels with Rat MAb MEC 13.3
The ultrastructural distribution of CD31 was studied in the microvessels of normal organs that displayed a continuous (skin, heart, lung), fenestrated (kidney, adrenal), or discontinuous (liver) endothelium (Feng et al. 2002Go). MEC 13.3 gave a consistent staining pattern in all of these tissues, i.e., strong labeling of the luminal and abluminal plasma membranes, significantly less labeling of the lateral plasma membranes, and no staining of interendothelial cell tight or adherens junctions (Figures 1 3) . These findings were most thoroughly documented in the continuous, non-fenestrated endothelium of skin, lung, and heart, where plasma membrane labeling was quantitated (p<0.001, Table 1).



View larger version (146K):
[in this window]
[in a new window]
 
Figure 1

Localization of CD31 in mouse endothelial cells with a rat MAb (13.3) and an ultrastructural immunonanogold method. (A) Luminal and abluminal plasma membranes of thin, discontinuous endothelium in mouse liver are labeled. Areas of endothelial discontinuity are indicated by arrows. The underlying epithelial cells are not labeled. Bar = 270 nm. (B) Thin, continuous fenestrated endothelium in mouse adrenal is labeled; the underlying adrenal epithelial cells are not labeled. Bar = 360 nm. (C) Thin continuous fenestrated glomerular endothelium of mouse kidney is labeled. Several silver-enhanced gold particles label individual diaphragm-guarded fenestra (closed arrow). The overlying epithelial cell foot processes, their slit diaphragms (open arrow) and the combined endothelial cell–epithelial cell basal lamina between these cell layers are not labeled. Bar = 180 nm. (D) Control (omission of the specific primary antibody) preparation of mouse kidney shows no label of epithelial foot processes (1), basal lamina (2), or glomerular endothelium (3). Bar = 240 nm. (E) Luminal and abluminal plasma membranes are labeled in the continuous non-fenestrated endothelium of mouse heart, which displays a large number of surface-attached caveolae. Underlying cardiac muscle is not labeled. Bar = 420 nm. (F) Luminal and abluminal plasma membranes of the continuous, non-fenestrated alveolar capillary endothelium in nude mouse lung are labeled. Note the large number of caveolae in the vessel, some of which are also labeled. The underlying alveolar epithelial cells are not labeled. L, Lumen. Bar = 260 nm.

 


View larger version (173K):
[in this window]
[in a new window]
 
Figure 3

CD31 localization to continuous, non-fenestrated endothelium in mouse skin with antibody 13.3. (A) Extensive label is present, associated with endothelial cell luminal and abluminal plasma membranes and cytoplasmic VVOs. The lateral plasma membranes of the interendothelial cell cleft and the tight junction (arrowhead) are not labeled. However, label is found at the introit (arrow) and exit flaps (arrows) of endothelial cells comprising the entrance to the interendothelial cell cleft. Bar = 150 nm. (B) Deeply invaginated endothelial cell shows extensive labeling of cytoplasmic VVOs and abluminal plasma membrane. Bar = 170 nm. (C) Invagination from the vascular lumen (L) is labeled, as are several VVO vesicles and vacuoles and the abluminal plasma membrane. Bar = 180 nm. (D) Control sample (substitution of irrelevant rat IgG for the specific primary antibody to CD31) shows VVO vesicles and vacuoles spanning the endothelium from lumen to ablumen; stomata and stomatal diaphragms are clearly illustrated. Label is absent. Bar = 190 nm. L, lumen.

 


View larger version (146K):
[in this window]
[in a new window]
 
Figure 2

Higher-magnification views localize CD31 to continuous, non-fenestrated endothelium in capillaries of normal A/Jax mouse heart (A) and nude mouse lung (B) with antibody 13.3. (A) Label overlies luminal and abluminal plasma membranes. The lateral plasma membranes of the interendothelial cell cleft (open arrowhead) and tight junction (closed arrowhead) and underlying myocardial muscle are not labeled. Bar = 290 nm. (B) Endothelial abluminal and luminal plasma membranes are labeled; the interendothelial cell tight junction (closed arrowhead) and lateral plasma membranes of the cleft (open arrowhead) and the underlying alveolar epithelial cell are not labeled. Bar = 170 nm. L, lumen.

 

View this table:
[in this window]
[in a new window]
 
Table 1

Monoclonal antibody MEC 13.3 immunonanogold quantitation of CD 31 in microvessel endothelial cell plasma membranes and VVOs of normal mouse skin, lung, and heart and in new blood vessels induced by VEGF-A164 or TA3/St tumor cells

 
CD31 was also localized (Figure 3) to a significant fraction of the vesicles and vacuoles comprising vesiculovacuolar organelles (VVOs) (12–16% in several normal mouse tissues; Table 1). VVOs are clusters of uncoated, largely parajunctional vesicles and vacuoles found in venular endothelial cells. They are interconnected by stomata that are normally closed by thin diaphragms but that open in response to VEGF-A and other vasoactive agents to provide a transcellular pathway for plasma extravasation. Focal deep invaginations of the endothelial cell plasma membranes were also extensively labeled (Figure 3B). These structures may derive from VVOs (Feng et al. 1999Go). Other endothelial cell cytoplasmic organelles, such as mitochondria and multivesicular bodies, were not labeled. Parenchymal cells, pericytes, and basal laminae did not stain with this antibody, but platelets and neutrophils incidentally present in vascular lumens exhibited strong plasma membrane staining (not shown).

Ultrastructural Distribution of CD31 on Angiogenic Microvessels with Rat MAb MEC 13.3
The distribution and intensity of CD31 labeling in the new microvessels induced by either the TA3/St mammary adenocarcinoma (Figure 4) or by an adenoviral vector engineered to express VEGF-A164 (Figure 5) was similar to that observed in normal blood vessels (Table 1). The luminal and abluminal surfaces of vascular endothelium showed strong and roughly equivalent labeling, whereas the lateral surfaces had comparatively little labeling (p<0.001). Approximately 12% of VVO vesicles and vacuoles were labeled, comparable to that observed in normal microvessels. Specialized interendothelial cell junctions (adherens, tight) exhibited no staining (Figures 5A and 5C). Pericytes, basal laminae, tumor cells, and other tissue cells did not stain with this antibody. However, as in normal tissues, circulating monocytes and neutrophils did exhibit plasma membrane labeling as well as labeling of some internal cytoplasmic endocytic/secretory vesicles and granule membranes (not shown).



View larger version (69K):
[in this window]
[in a new window]
 
Figure 4

CD31 localization with antibody 13.3 in subcutaneous tumor-associated vessels 9 days after implantation of TA3/St mouse mammary tumor. Luminal, and to a lesser extent abluminal, plasma membrane is labeled, whereas the long segment of lateral plasma membranes that form the intercellular cleft between two endothelial cells is not. Two particles are bound to the luminal flap of one endothelial cell at the luminal introit of the lateral interendothelial cell cleft (arrow). L, lumen. Bar = 260 nm.

 


View larger version (122K):
[in this window]
[in a new window]
 
Figure 5

CD31 localization with antibody 13.3 in angiogenic vessels generated in nude mouse skin 4 days after injection of Ad-VEGF-A164. (A) Luminal plasma membrane of mother vessel endothelial cell is labeled. The extensive interendothelial cell cleft composed of lateral plasma membranes of two cells and their focal tight junctions (arrows) are not labeled. Bar = 310 nm. (B) Thicker endothelial cell portion of a new vessel is packed with labeled VVOs; the abluminal and luminal plasma membranes are also labeled. Bar = 240 nm. (C) High-magnification view of two endothelial cells shows no label on the lateral plasma membranes or on junctional complexes. One silver-enhanced gold particle rests in the cytoplasm near the interendothelial cell junction. L, lumen. Bar = 120 nm.

 
Ultrastructural Distribution of CD31 on Microvessels with a Goat Polyclonal Antibody Directed Against a CD31 Terminal Peptide (M-20)
Antibody M-20 gave a labeling distribution that was distinctly different from that of MEC 13.3 (Figures 6 and 7) . The lateral plasma membranes of apposed microvascular endothelial cells were strongly and selectively labeled, both in normal tissues and in the new microvessels induced by Ad-VEGF-A164, whereas the luminal and abluminal plasma membranes were largely spared (Table 2). However, despite intense and selective labeling of the lateral endothelial membranes, tight junctions and adherens junctions were not labeled (Figures 6A–6D). Consistent with the C-terminal localization of the antigen, staining was localized to the inner face of the plasma membrane (Figures 6 and 7A). M-20 also stained a significant minority of VVO vesicles and vacuoles (17–23%; Table 2), predominantly on their cytoplasmic face (Figure 7B).



View larger version (172K):
[in this window]
[in a new window]
 
Figure 6

Immunonanogold staining of endothelial cells in Ad-VEGF-A164 expressing (A,C,D) or nude (B) control mouse skin with antibody M-20 directed against the C-terminal peptide of CD31. (A) Most of the label is associated with the lateral endothelial cell plasma membranes (arrows) and with VVOs (see cytoplasmic area at right of photograph). Some label is bound to the abluminal and luminal plasma membranes. Note that the tight junction between two endothelial cells (arrowhead) near the vascular lumen (L) is devoid of label. (B–D) Higher magnifications. These panels show CD31 C-terminal peptide located in apposed lateral membranes of adjacent endothelial cells. Focal tight junctions (arrowheads) of the intercellular cleft region are not labeled. Bars: A = 700 nm; B = 170 nm; C = 160 nm; D = 150 nm.

 


View larger version (149K):
[in this window]
[in a new window]
 
Figure 7

Immunonanogold staining of endothelial cells in normal mouse skin with antibody M-20. (A) High-magnification view of interendothelial cell plasma membrane shows extensive labeling, largely confined to the cytoplasmic face. Bar = 350 nm. (B) Heavily labeled VVO. Most of the label is attached to the cytoplasmic face of the vesicle and vacuole membranes. Bar = 380 nm.

 

View this table:
[in this window]
[in a new window]
 
Table 2

Polyclonal goat antibody M-20 immunonanogold quantitation of CD31 in microvessel endothelial cell plasma membranes and VVOs in normal mouse skin and in the new blood vessels induced by VEGF-A164

 
Studies in CD31-null Mice
We considered the possibility that the disparate staining pattern observed was attributable to a lack of specificity of one or both of our antibodies. Therefore, we repeated our immunocytochemical studies on the normal tissues (skin, kidney) of CD31-null and control mice. In contrast to strong staining in B6;129S-F2/J controls, neither antibody stained the microvessels of CD31-null B6;129S-Pecamtm1Lex mice (Figure 8) .



View larger version (138K):
[in this window]
[in a new window]
 
Figure 8

Immunonanogold preparations of skin endothelium of wild-type (A,B) and CD31 knockout (C,D) mice. (A,C) Stained with primary antibody M-20, specific for the C-terminal peptide of CD31. (B) Stained with an irrelevant IgG substituted for the primary antibody. (D) Stained with primary antibody 13.3. (A) Lateral endothelial cell plasma membranes of wild-type mouse endothelium are precisely labeled with the M-20 antibody and very few gold particles label the luminal or abluminal plasma membranes; tight junctions between endothelial cells are not labeled (arrowheads). Bar = 600 nm. (B) The irrelevant IgG control is negative. Neither antibody M-20 (C) nor antibody 13.3 (D) stained endothelial plasma membranes, intercellular cleft, junctions, or cytoplasmic VVOs and vesicles of CD31 knockout mice. Bar = 400 nm.

 
Ultrastructural Distribution of VE-Cadherin in Microvascular Endothelium
New blood vessels induced by tumors or Ad-VEGF-A164 localized VE-cadherin to the cytoplasmic faces of adherens junctions (Figures 9A and 9C) . Normal microvessels exhibited a similar pattern of staining, although somewhat less intense. Luminal and abluminal plasma membranes, VVOs, and coated vesicles were not stained (Figures 9A, 9C, and 9D). An irrelevant antibody control was negative (Figure 9B).



View larger version (159K):
[in this window]
[in a new window]
 
Figure 9

VE-cadherin immunonanogold localization in microvessels from Ad-VEGF-A164 injected mouse skin at 5 days (A) and in TA3/St subcutaneous mammary tumor microvessels 9 days after innoculation in mouse skin (C,D). VE-cadherin is present in the cytoplasmic side of apposed lateral plasma membranes of endothelial cells at the sites of junctions (A,C). The luminal and abluminal plasma membranes are not labeled (A,C,D) nor are VVOs (D) or coated vesicles (arrow, D). (B) Nude mouse skin 5 days after injection of Ad-VEGF-A164. An irrelevant (control) antibody does not label the lateral plasma membrane compartment (arrowheads), junctions, or VVO vesicles and vacuoles. L, lumen. Bars: A = 140 nm; B = 215 nm; C = 110 nm; D = 160 nm.

 
Specificity Controls for the Immunogold Procedure
All four controls (see Materials and Methods) were negative. Illustrated are omission of the primary antibody (Figure 1D) and substitution of an irrelevant IgG for specific primary antibodies (Figures 3D and 9B). We also examined skin endothelial cells in CD31 knockout mice (Figures 8C and 8D), which gave no staining of plasma membranes or of VVOs with either MEC 13.3 or M-20.


    Discussion
 Top
 Summary
 Introduction
 Materials and Methods
 Results
 Discussion
 Literature Cited
 
The distribution of CD31 on vascular endothelium has been a matter of dispute. Although distributed evenly over the surface of non-confluent cultured endothelial cells, CD31 was reported to become highly concentrated at interendothelial cell contacts both in vivo and in vitro (Muller et al. 1989Go; Albelda et al. 1991Go), and this view has been widely accepted in the literature (see Scholz and Schaper 1997Go for complete references). On the other hand, Grafe et al. (1994)Go, Scholz and Schaper (1997)Go, and others (Erhard et al. 1996Go; Sauter et al. 1998Go) have reported that CD31 was homogeneously distributed over the entire endothelial cell surface, luminal and abluminal as well as lateral, both in vitro and in vivo. Scholz and Schaper (1997)Go used confocal and immunocytochemical electron microscopy to study five different mouse MAbs and a rabbit polyclonal antibody directed against human CD31. Some of the antibodies used in these studies had been provided by authors who had previously used them to localize CD31 to the cell–cell interface. Scholz and Schaper (1997)Go noted that most of the earlier studies that claimed a junctional localization had been performed on cultured endothelium using light microscopic IHC or immunofluorescence and may not have fully taken into account anatomic features that would artifactually accentuate staining at intercellular contacts (e.g., overlapping membranes of apposed endothelial cells could give the appearance of increased interface staining). However, none of the investigators to date made any attempt to quantitate CD31 epitope density in different regions of the endothelial cell plasma membrane.

In an attempt to clarify the issue of CD31 distribution on vascular endothelium, we used a pre-embedding immunonanogold electron microscopic procedure that allowed precise subcellular localization and quantitation of CD31 epitope distribution (Feng et al. 2000aGo). Using two different antibodies to mouse CD31 that have not been previously investigated at the electron microscopic level, we found strikingly different labeling patterns in mouse microvascular endothelium. A much studied blocking antibody, MEC 13.3, reacted strongly with the extracellular face of the luminal and abluminal plasma membranes of microvascular endothelial cells but displayed only minor labeling of the lateral plasma membranes (Figures 1 5; Table 1). This labeling pattern was similar in several normal tissues, in TA3/St tumor vessels, and in the angiogenic vessels induced by Ad-VEGF-A164. In contrast, a polyclonal antibody, M-20, directed against a C-terminal peptide of CD31, strongly labeled the cytoplasmic face of the lateral plasma membranes of endothelial cells, although sparing tight and adherens junctions. The luminal and abluminal membranes were labeled to a much lesser extent (Figures 6 and 7; Table 2). Given the significantly different distributions of CD31 observed with these two antibodies (Figure 10) , we considered the possibility that one or both were not specific for CD31. However, neither antibody reacted with vascular endothelium (or leukocytes or platelets) in CD31-null mice (Figure 8), providing strong evidence that both were indeed specific for CD31.



View larger version (22K):
[in this window]
[in a new window]
 
Figure 10

Schematic diagram illustrating labeling pattern of MEC 13.3 (blue dots) and M-20 (red dots) in vascular endothelium. MEC 13.3 primarily labels the external surfaces of luminal and abluminal surface membranes, whereas M-20 primarily labels the cytoplasmic face of lateral plasma membranes. Both antibodies label a fraction of VVO vesicles and vacuoles. M13.3 label was found predominantly on the inner vesicular/vacuolar face, whereas M-20 staining was predominantly on the cytoplasmic face, Neither labeled specialized adherens or tight junctions.

 
We conclude that CD31 is distributed over the entire endothelial cell surface, luminal, abluminal, and lateral, with the exception of specialized intercellular junctions, as also previously reported (Lampugnani et al. 1992Go; Ayalon et al. 1994Go). Failure to stain specialized junctions with either antibody cannot be attributed to poor antibody penetration because adherens junctions were strongly and selectively stained with an antibody to VE-cadherin (Figure 9).

We do not have a clear explanation for the striking quantitative differences in CD31 distribution exhibited by the two antibodies we studied, although they probably relate to their recognition of different CD31 epitopes. The polyclonal M-20 antibody recognizes a cytoplasmic epitope of CD31. Therefore, one possibility is that the cytoplasmic portion of CD31 molecules distributed in the luminal and abluminal plasma membranes form complexes with other cytoplasmic proteins that make them inaccessible to the M-20 antibody. Another possible explanation relates to the fact that the cytoplasmic portion of CD31 has multiple splicing variants (Sheibani et al. 1999Go; Jackson 2003Go; Newman and Newman 2003Go). It is not known whether these different splicing variants are distributed differently in different sites in the vascular endothelium. If so, it is possible that the C-terminal epitope of CD31 that is recognized by the M-20 antibody is preferentially expressed by CD31 molecules localized in the lateral plasma membrane. New antibodies directed against different CD31 cytoplasmic epitopes will be needed to address this question.

Alternative splicing might not have been expected to prevent MEC 13.3 from labeling the lateral plasma membranes more strongly, because splice variants described thus far have been confined to the cytoplasmic portion of CD31. However, different splicing variants of the cytoplasmic tail of CD31 have been shown to affect CD31 binding (Baldwin et al. 1994Go; DeLisser et al. 1994Go; Yan et al. 1995Go; Famiglietti et al. 1997Go). A more likely explanation for the failure of MEC 13.3 to label lateral endothelial cell plasma membranes is that MEC 13.3 reacts with extracellular epitopes of CD31 that are engaged in homotypic bonds between adjacent endothelial cells and therefore are unavailable for binding to antibody.

In addition to labeling the plasma membrane of endothelial cells, both MEC 13.3 and M-20 antibodies labeled a significant fraction (12–20%) of VVO vesicles and vacuoles. VVOs represent an important pathway for transcellular passage of macromolecules and fluid in response to vascular permeabilizing mediators such as VEGF-A (Dvorak et al. 1996Go; Feng et al. 1996Go,1999Go). They may also have a role in neutrophil diapedesis (Feng et al. 1998Go) and may provide a substantial store of membrane that can be rapidly mobilized to the cell surface early in angiogenesis to allow the rapid expansion in cell surface area that accompanies vessel enlargement (formation of "mother" vessels) (Pettersson et al. 2000Go; Nagy et al. 2002Go). CD31 has been reported to have a role in both vascular permeability and angiogenesis (Zhou et al. 1999Go; Cao et al. 2002Go; Graesser et al. 2002Go), and CD31 represented on VVOs could be involved. Finally, because VVOs are often parajunctional, their staining with antibodies to CD31 may also have contributed to the idea that CD31 is preferentially located at the interface between adjacent endothelial cells. By light microscopy, it may not have been possible to distinguish IHC reaction product located in VVOs from that localized to the lateral plasma membrane of endothelial cells.

It remains unclear exactly how antibodies to CD31 inhibit leukocyte migration. A recent report (O'Brien et al. 2003Go) describes five mechanisms by which CD31 could modulate the neutrophil migration across endothelial cell monolayers that is induced by cytokines (e.g., IL-1ß). The authors also note that transendothelial migration induced by neutrophil chemoattractants (LTB4) or chemokines (IL-8) is CD31-independent. Blocking antibodies are reported to have limited access to CD31 molecules at the interface between adjacent endothelial cells (Muller et al. 1993Go). Therefore, such antibodies may act in other ways, binding to CD31 expressed on leukocytes, on the luminal surface of endothelial cells, or on VVOs. The Muller laboratory has provided strong evidence that antibodies to CD31 that inhibit transmigration do not prevent adherence of leukocytes to the apical surface of vascular endothelium (Muller et al. 1993Go; Liao et al. 1995Go). Therefore, attachment of leukocytes to endothelium is not dependent on CD31, whereas transmigration of leukocytes is, at least for certain stimuli. Blocking antibodies could also act by interfering with cell signaling mechanisms (Newton–Nash and Newman 1999Go; Henshall et al. 2001Go; Ilan et al. 2001Go; Newman et al. 2001Go; O'Brien et al. 2003Go).

Our finding of CD31 labeling of VVO vesicles and vacuoles relates to a recent paper that described a population of CD31-positive vesicles located just beneath the plasmalemma at the borders of cultured human endothelial cells (Mamdouh et al. 2003Go). These vesicles were found to recycle evenly along endothelial cell borders but, during leukocyte emigration, were targeted to segments of the border across which monocytes were migrating. They were believed to facilitate monocyte emigration because blocking antibodies to CD31 specifically inhibited the recruitment of these vesicles to zones of leukocyte migration. The authors concluded that their vesicles were not caveolae or associated with VVOs because CD31 and caveolin staining did not co-localize. However, VVO vesicles and vacuoles are commonly parajunctional, and individual VVO vesicles not uncommonly fuse to the lateral plasmalemma (see Figure 1 in Feng et al. 1997Go). It therefore remains to be determined whether the vesicles described by Mamdouh et al. (2003)Go represent an entirely new population of vesicles or one that is related to VVOs.

In summary, we have shown that CD31 is localized to the entire surface of vascular endothelial cells in both normal tissues and in tumor and Ad-VEGF-A164-induced angiogenesis. However, two different authenticated antibodies gave significantly different distributions on the endothelial cell surface (Figure 10). In addition, both antibodies reacted with a significant fraction of VVO vesicles and vacuoles. Further work will be required to elucidate the reasons for these differences and to work out the role played by CD31 in inflammatory cell diapedesis.


    Acknowledgments
 
Supported in part by US Public Health Service grants CA-50453, HL-59316, and P01 CA92644 (HFD), AI-33372 and AI-44066 (AMD), and by a contract from the National Foundation for Cancer Research (HFD).


    Footnotes
 
Received for publication June 16, 2003; accepted September 24, 2003


    Literature Cited
 Top
 Summary
 Introduction
 Materials and Methods
 Results
 Discussion
 Literature Cited
 

Albelda SM, Muller WA, Buck CA, Newman PJ (1991) Molecular and cellular properties of PECAM-1 (endoCAM/CD31): a novel vascular cell-cell adhesion molecule. J Cell Biol 114:1059–1068[Abstract]

Albelda SM, Oliver PD, Romer LH, Buck CA (1990) EndoCAM: a novel endothelial cell-cell adhesion molecule. J Cell Biol 110: 1227–1237[Abstract]

Ayalon O, Sabanai H, Lampugnani MG, Dejana E, Geiger B (1994) Spatial and temporal relationships between cadherins and PECAM-1 in cell-cell junctions of human endothelial cells. J Cell Biol 126:247–258[Abstract]

Baldwin HS, Shen HM, Yan HC, DeLisser HM, Chung A, Mickanin C, Trask T, et al. (1994) Platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31): alternatively spliced, functionally distinct isoforms expressed during mammalian cardiovascular development. Development 120:2539–2553[Abstract/Free Full Text]

Bogen SA, Baldwin HS, Watkins SC, Albelda SM, Abbas AK (1992) Association of murine CD31 with transmigrating lymphocytes following antigenic stimulation. Am J Pathol 141:843–854[Abstract]

Cao G, O'Brien CD, Zhou Z, Sanders SM, Greenbaum JN, Makrigiannakis A, DeLisser HM (2002) Involvement of human PECAM-1 in angiogenesis and in vitro endothelial cell migration. Am J Physiol 282:C1181–1190

Carlos TM, Harlan JM (1994) Leukocyte-endothelial adhesion molecules. Blood 84:2068–2101[Abstract/Free Full Text]

Christofidou–Solomidou M, Nakada MT, Williams J, Muller WA, DeLisser HM (1997) Neutrophil platelet endothelial cell adhesion molecule-1 participates in neutrophil recruitment at inflammatory sites and is down-regulated after leukocyte extravasation. J Immunol 158:4872–4878[Abstract]

Cicmil M, Thomas JM, Leduc M, Bon C, Gibbins JM (2002) Platelet endothelial cell adhesion molecule-1 signaling inhibits the activation of human platelets. Blood 99:137–144[Abstract/Free Full Text]

DeLisser HM, Chilkotowsky J, Yan HC, Daise ML, Buck CA, Albelda SM (1994) Deletions in the cytoplasmic domain of platelet-endothelial cell adhesion molecule-1 (PECAM-1, CD31) result in changes in ligand binding properties. J Cell Biol 124:195–203[Abstract]

DeLisser HM, Christofidou–Solomidou M, Strieter RM, Burdick MD, Robinson CS, Wexler RS, Kerr JS, et al. (1997) Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol 151:671–677[Abstract]

Dvorak AM, Kohn S, Morgan ES, Fox P, Nagy JA, Dvorak HF (1996) The vesiculo-vacuolar organelle (VVO): a distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation. J Leukocyte Biol 59:100–115[Abstract]

Ebata N, Sawa Y, Nodasaka Y, Yamaoka Y, Yoshida S, Totsuka Y (2001) Immunoelectron microscopic study of PECAM-1 expression on lymphatic endothelium of the human tongue. Tissue Cell 33:211–218[Medline]

Erhard H, Rietveld FJ, Brocker EB, de Waal RM, Ruiter DJ (1996) Phenotype of normal cutaneous microvasculature. Immunoelectron microscopic observations with emphasis on the differences between blood vessels and lymphatics. J Invest Dermatol 106:135–140[Abstract]

Famiglietti J, Sun J, DeLisser HM, Albelda SM (1997) Tyrosine residue in exon 14 of the cytoplasmic domain of platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) regulates ligand binding specificity. J Cell Biol 138:1425–1435[Abstract/Free Full Text]

Feng D, Nagy JA, Brekken RA, Pettersson A, Manseau EJ, Pyne K, Mulligan R, et al. (2000a) Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumors and adenoviral vectors. J Histochem Cytochem 48:545–556[Abstract/Free Full Text]

Feng D, Nagy JA, Dvorak AM, Dvorak HF (2000b) Different pathways of macromolecule extravasation from hyperpermeable tumor vessels. Microvasc Res 59:24–37[Medline]

Feng D, Nagy J, Dvorak H, Dvorak A (2002) Ultrastructural studies define soluble macromolecular, particulate, and cellular transendothelial cell pathways in venules, lymphatic vessels, and tumor-associated microvessels in man and animals. Microsc Res Tech 57:289–326[Medline]

Feng D, Nagy JA, Hipp J, Dvorak HF, Dvorak AM (1996) Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. J Exp Med 183:1981–1986[Abstract]

Feng D, Nagy JA, Hipp J, Pyne K, Dvorak HF, Dvorak AM (1997) Reinterpretation of endothelial cell gaps induced by vasoactive mediators in guinea-pig, mouse and rat: many are transcellular pores. J Physiol 504(pt 3):747–761

Feng D, Nagy JA, Pyne K, Dvorak HF, Dvorak AM (1998) Neutrophils emigrate from venules by a transendothelial cell pathway in response to FMLP. J Exp Med 187:903–915[Abstract/Free Full Text]

Feng D, Nagy JA, Pyne K, Hammel I, Dvorak HF, Dvorak AM (1999) Pathways of macromolecular extravasation across microvascular endothelium in response to VPF/VEGF and other vasoactive mediators. Microcirculation 6:23–44[Medline]

Graesser D, Solowiej A, Bruckner M, Osterweil E, Juedes A, Davis S, Ruddle NH, et al. (2002) Altered vascular permeability and early onset of experimental autoimmune encephalomyelitis in PECAM-1-deficient mice. J Clin Invest 109:383–392[Abstract/Free Full Text]

Grafe M, Auch–Schwelk W, Graf K, Terbeek D, Hertel H, Unkelbach M, Hildebrandt A, et al. (1994) Isolation and characterization of macrovascular and microvascular endothelial cells from human hearts. Am J Physiol 267:H2138–2148[Medline]

Henshall TL, Jones KL, Wilkinson R, Jackson DE (2001) Src homology 2 domain-containing protein-tyrosine phosphatases, SHP-1 and SHP-2, are required for platelet endothelial cell adhesion molecule-1/CD31-mediated inhibitory signaling. J Immunol 166:3098–3106[Abstract/Free Full Text]

Ilan N, Mohsenin A, Cheung L, Madri JA (2001) PECAM-1 shedding during apoptosis generates a membrane-anchored truncated molecule with unique signaling characteristics. FASEB J 15:362–372[Abstract/Free Full Text]

Ioffreda MD, Albelda SM, Elder DE, Radu A, Leventhal LC, Zweiman B, Murphy GF (1993) TNFa induces E-selectin expression and PECAM-1 (CD31) redistribution in extracutaneous tissues. Endothelium 1:47–54

Jackson DE (2003) The unfolding tale of PECAM-1. FEBS Lett 540:7–14[Medline]

Lampugnani MG, Resnati M, Raiteri M, Pigott R, Pisacane A, Houen G, Ruco LP, et al. (1992) A novel endothelial-specific membrane protein is a marker of cell-cell contacts. J Cell Biol 118:1511–1522[Abstract]

Liao F, Huynh HK, Eiroa A, Greene T, Polizzi E, Muller WA (1995) Migration of monocytes across endothelium and passage through extracellular matrix involve separate molecular domains of PECAM-1. J Exp Med 182:1337–1343[Abstract]

Liao F, Schenkel AR, Muller WA (1999) Transgenic mice expressing different levels of soluble platelet/endothelial cell adhesion molecule-IgG display distinct inflammatory phenotypes. J Immunol 163:5640–5648[Abstract/Free Full Text]

Lossinsky AS, Wisniewski HM (1998) Immunoultrastructural expression of ICAM-1 and PECAM-1 occurs prior to structural maturity of the murine blood-brain barrier. Dev Neurosci 20:518–524[Medline]

Mamdouh Z, Chen X, Pierini LM, Maxfield FR, Muller WA (2003) Targeted recycling of PECAM from endothelial surface-connected compartments during diapedesis. Nature 421:748–753[Medline]

Marszalek A, Daa T, Kashima K, Nakayama I, Yokoyama S (2000) Ultrastructural and morphometric studies related to expression of the cell adhesion molecule PECAM-1/CD31 in developing rat lung. J Histochem Cytochem 48:1283–1289[Abstract/Free Full Text]

Metzelaar MJ, Korteweg J, Sixma JJ, Nieuwenhuis HK (1991) Biochemical characterization of PECAM-1 (CD31 antigen) on human platelets. Thromb Haemost 66:700–707[Medline]

Muller WA (1995a) The role of PECAM-1 (CD31) in leukocyte emigration: studies in vitro and in vivo. J Leukocyte Biol 57:523–528[Abstract]

Muller WA (1995b) The use of anti-PECAM reagents in the control of inflammation. Agents Actions Suppl 46:147–157[Medline]

Muller WA, Randolph GJ (1999) Migration of leukocytes across endothelium and beyond: molecules involved in the transmigration and fate of monocytes. J Leukocyte Biol 66:698–704[Abstract]

Muller WA, Ratti CM, McDonnell SL, Cohn ZA (1989) A human endothelial cell-restricted, externally disposed plasmalemmal protein enriched in intercellular junctions. J Exp Med 170:399–414[Abstract]

Muller WA, Weigl SA, Deng X, Phillips DM (1993) PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med 178:449–460[Abstract]

Murohara T, Delyani JA, Albelda SM, Lefer AM (1996) Blockade of platelet endothelial cell adhesion molecule-1 protects against myocardial ischemia and reperfusion injury in cats. J Immunol 156:3550–3557[Abstract]

Nagy JA, Vasile E, Feng D, Sundberg C, Brown LF, Manseau EJ, Dvorak AM, et al. (2002) VEGF-A induces angiogenesis, arteriogenesis, lymphangiogenesis, and vascular malformations. In Cold Spring Harbor Symposia on Quantitative Biology. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press

Newman PJ (1994) The role of PECAM-1 in vascular cell biology. Ann NY Acad Sci 714:165–174[Abstract]

Newman PJ (1997) The biology of PECAM-1. J Clin Invest 100:S25–29[Medline]

Newman DK, Hamilton C, Newman PJ (2001) Inhibition of antigen-receptor signaling by platelet endothelial cell adhesion molecule-1 (CD31) requires functional ITIMs, SHP-2, and p56(lck). Blood 97:2351–2357[Abstract/Free Full Text]

Newman PJ, Hillery CA, Albrecht R, Parise LV, Berndt MC, Mazurov AV, Dunlop LC, et al. (1992) Activation-dependent changes in human platelet PECAM-1: phosphorylation, cytoskeletal association, and surface membrane redistribution. J Cell Biol 119:239–246[Abstract]

Newman PJ, Newman DK (2003) Signal transduction pathways mediated by PECAM-1. New roles for an old molecule in platelet and vascular cell biology. Arterioscler Thromb Vasc Biol 23:953–964.[Abstract/Free Full Text]

Newton–Nash DK, Newman PJ (1999) A new role for platelet-endothelial cell adhesion molecule-1 (CD31): inhibition of TCR-mediated signal transduction. J Immunol 163:682–688[Abstract/Free Full Text]

O'Brien CD, Lim P, Sun J, Albelda SM (2003) PECAM-1-dependent neutrophil transmigration is independent of monolayer PECAM-1 signaling or localization. Blood 101:2816–2825[Abstract/Free Full Text]

Ohto H, Maeda H, Shibata Y, Chen RF, Ozaki Y, Higashihara M, Takeuchi A, et al. (1985) A novel leukocyte differentiation antigen: two monoclonal antibodies TM2 and TM3 define a 120-kd molecule present on neutrophils, monocytes, platelets, and activated lymphoblasts. Blood 66:873–881[Abstract]

Pettersson A, Nagy JA, Brown LF, Sundberg C, Morgan E, Jungles S, Carter R, et al. (2000) Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest 80:99–115[Medline]

Rival Y, Del Maschio A, Rabiet MJ, Dejana E, Duperray A (1996) Inhibition of platelet endothelial cell adhesion molecule-1 synthesis and leukocyte transmigration in endothelial cells by the combined action of TNF-alpha and IFN-gamma. J Immunol 157:1233–1241[Abstract]

Sauter B, Foedinger D, Sterniczky B, Wolff K, Rappersberger K (1998) Immunoelectron microscopic characterization of human dermal lymphatic microvascular endothelial cells. Differential expression of CD31, CD34, and type IV collagen with lymphatic endothelial cells vs blood capillary endothelial cells in normal human skin, lymphangioma, and hemangioma in situ. J Histochem Cytochem 46:165–176[Abstract/Free Full Text]

Schimmenti LA, Yan HC, Madri JA, Albelda SM (1992) Platelet endothelial cell adhesion molecule, PECAM-1, modulates cell migration. J Cell Physiol 153:417–428[Medline]

Scholz D, Schaper J (1997) Platelet/endothelial cell adhesion molecule-1 (PECAM-1) is localized over the entire plasma membrane of endothelial cells. Cell Tissue Res 290:623–631[Medline]

Sheibani N, Sorenson CM, Frazier WA (1999) Tissue specific expression of alternatively spliced murine PECAM-1 isoforms. Dev Dyn 214:44–54[Medline]

Vaporciyan AA, DeLisser HM, Yan HC, Mendiguren II, Thom SR, Jones ML, Ward PA, et al. (1993) Involvement of platelet-endothelial cell adhesion molecule-1 in neutrophil recruitment in vivo. Science 262:1580–1582[Medline]

Vecchi A, Garlanda C, Lampugnani MG, Resnati M, Matteucci C, Stoppacciaro A, Schnurch H, et al. (1994) Monoclonal antibodies specific for endothelial cells of mouse blood vessels. Their application in the identification of adult and embryonic endothelium. Eur J Cell Biol 63:247–254[Medline]

Yan HC, Baldwin HS, Sun J, Buck CA, Albelda SM, DeLisser HM (1995) Alternative splicing of a specific cytoplasmic exon alters the binding characteristics of murine platelet/endothelial cell adhesion molecule-1 (PECAM-1). J Biol Chem 270:23672–23680[Abstract/Free Full Text]

Zhou Z, Christofidou–Solomidou M, Garlanda C, DeLisser HM (1999) Antibody against murine PECAM-1 inhibits tumor angiogenesis in mice. Angiogenesis 3:181–188

Zocchi MR, Ferrero E, Leone BE, Rovere P, Bianchi E, Toninelli E, Pardi R (1996) CD31/PECAM-1-driven chemokine-independent transmigration of human T lymphocytes. Eur J Immunol 26: 759–767[Medline]